Drugs / Pitavastatin
Pitavastatin
also known as
NK-104 · LIVALO · pitavastatin Ca · Pitavastatin calcium · Itavastatin calcium · Livalo Tab 1 mg · Livaro · Minshilang · +10 more
Small molecule targets HMGCR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | LIVALO | — | 2016-11-18 – 2019-05-16 | fda.gov ↗ |
| Approved | US (FDA) | LIVALO | — | 2009-08-03 | fda.gov ↗ |
Trials 73 · started per year
today
US approved 2009
5
5
2
2
2
6
4
1
2
2
5
4
2
3
3
3
2
2
3
2
4
9
20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05977738 | Jan → Jul 2024 | adult glioblastoma | C.Dirven | Completed | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT07774975 | Oct 2026 → Jan 2028 expected | retinitis pigmentosa | Kyushu University | Recruiting | No outcome recorded |
| Phase 1 | NCT07784621 | Oct 2026 → Feb 2027 expected | hypertensive disorder | Huons Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07726368 | Aug → Dec 2026 expected | NAFLD1, hyperlipidemia | Eccogene | Recruiting | No outcome recorded |
| Phase 1 | NCT07567781 | Apr → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07549958 | Mar 2026 → Mar 2027 expected | pancreatic adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1 | NCT07351565 | Jan → Jun 2026 overdue | non-small cell lung carcinoma | Chang Chen | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06982131 | Jun 2025 → Dec 2026 expected | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06813924 | Feb → May 2025 | inherited hemoglobinopathy | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06808646 | Jan → Feb 2025 | — | Basilea Pharmaceutica | Completed | No outcome recorded |
| Phase 1 | NCT05334108 | Apr → Aug 2022 | — | Emalex Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04764851 | Feb → Apr 2021 | — | Emalex Biosciences Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04512105 | Dec 2020 → Jul 2024 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia | University of California, Irvine | Completed | No outcome recorded |
| Phase 1 | NCT03717064 | Nov → Dec 2018 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03311841 | Mar → Aug 2018 | impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02888327 | Jul 2016 → May 2017 | influenza | Alios Biopharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02634034 | Dec 2015 | hyperlipidemia | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02595268 | Nov 2015 → Jan 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02250976 | Sep → Oct 2014 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01767610 | Jan → Mar 2013 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01695954 | May 2012 → Jan 2013 | HIV infectious disease, hyperlipidemia | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT01232049 | Oct 2010 → Mar 2011 | — | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01595828 | Oct 2010 → Jun 2012 | metabolic syndrome X | Kowa Research Europe | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06553157 | Sep 2024 → Jul 2025 | cancer, platinum-induced ototoxicity | Minia University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07460960 | Mar 2026 → Dec 2027 expected | atherosclerosis, vasculogenic impotence | Lomonosov Moscow State University Medical Research and Educational Center | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04705909 | Jan → Sep 2021 | breast cancer | Mansoura University | Unknown | Mixed |
| Phase 316 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT04289649 | Apr → Nov 2020 | hyperlipidemia | Kowa Company, Ltd. | Completed | Met primary |
| Phase 3 | NCT04289662 | Mar 2020 → Aug 2021 | hyperlipidemia | Kowa Company, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04584736 | Jun 2019 → Jul 2020 | hyperlipoproteinemia | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT03070223 | Mar 2017 → Aug 2023 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | Missed primary |
| Phase 3 | NCT02344290 | Mar 2015 → Aug 2023 | HIV infectious disease, cardiovascular disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT01386853 | Jul 2011 → Mar 2012 | hyperlipidemia | Tai Tien Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01402843 | Jun 2011 → Jun 2012 | hyperlipidemia, hypertensive disorder | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00344370 | Aug 2006 → Apr 2008 | hyperlipidemia, type 2 diabetes mellitus | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00325780 | Jul 2006 → Nov 2007 | hyperlipidemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00344175 | Jun 2006 → Aug 2007 | coronary artery disorder, hyperlipidemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00330876 | Jun 2006 → Dec 2007 | hyperlipidemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00309751 | Dec 2005 → Jun 2007 | hyperlipidemia, type 2 diabetes mellitus | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00249249 | Oct 2005 → Nov 2006 | hyperlipidemia, hyperlipoproteinemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00309738 | Sep 2005 → Oct 2006 | hyperlipidemia | Kowa Research Europe | Completed | Met primary |
| Phase 3 | NCT00257686 | Sep 2005 → May 2006 | hyperlipidemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00309777 | Sep 2005 → Oct 2006 | hyperlipidemia | Kowa Research Europe | Completed | Met primary |
| Phase 425 trials · 4 met primary · 1 missed | ||||||
| Phase 4 | NCT06767774 | Apr 2025 → Aug 2029 expected | atherosclerotic cardiovascular disease, diabetes mellitus | Korea University Anam Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07442630 | Aug 2023 → Jan 2026 overdue | hyperlipidemia | JW Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06273215 | Mar 2023 → Dec 2025 | diabetes mellitus | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05747768 | Jul 2022 → Jun 2024 | chronic kidney disease | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06359353 | Apr 2019 → Feb 2022 | hyperlipoproteinemia, postmenopausal osteoporosis | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03532620 | Aug 2018 → Sep 2019 | hyperlipidemia, hypertensive disorder, prediabetes syndrome | Jun Tao | Unknown | No outcome recorded |
| Phase 4 | NCT03418974 | Nov 2017 → Dec 2021 | hyperlipidemia | Fudan University | Unknown | No outcome recorded |
| Phase 4 | NCT02940366 | Dec 2016 → Nov 2019 | metabolic syndrome X | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02863185 | May 2016 → Dec 2020 | chronic kidney disease | Dong-A University | Completed | No outcome recorded |
| Phase 4 | NCT02743260 | Apr 2016 → Dec 2017 | — | University of Cologne | Completed | Met primary |
| Phase 4 | NCT04945122 | Oct 2015 → Dec 2022 | acute myocardial infarction, glucose metabolism disease | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02442700 | May 2014 → Jan 2015 | HIV infectious disease, hyperlipidemia | Ramathibodi Hospital | Completed | Met primary |
| Phase 4 | NCT01871792 | Jun 2013 → Feb 2014 | — | Gachon University Gil Medical Center | Unknown | Missed primary |
| Phase 4 | NCT01422382 | May → Jun 2011 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01422369 | Apr → Jun 2011 | — | Kowa Research Institute, Inc. | Completed | Mixed |
| Phase 4 | NCT01301066 | Dec 2010 → Mar 2013 | hyperlipidemia | Kowa Research Institute, Inc. | Completed | Met primary |
| Phase 4 | NCT01256476 | Oct 2010 → Jun 2011 | hyperlipidemia, combined, 2 | Kowa Research Institute, Inc. | Completed | Met primary |
| Phase 4 | NCT01178853 | Jul → Oct 2010 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01057433 | Jan → Dec 2010 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01043094 | Dec 2009 → Apr 2010 | — | Kowa Research Institute, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01166633 | Jun 2009 → Nov 2010 | hyperlipidemia | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT00786734 | Aug 2008 → May 2009 | — | JW Pharmaceutical | Withdrawn | No outcome recorded |
| Phase 4 | NCT00889226 | Apr 2008 → May 2009 | hyperlipidemia | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT00444717 | Apr 2007 → Sep 2008 | metabolic syndrome X | Aichi Gakuin University | Completed | No outcome recorded |
| Phase 4 | NCT00301392 | Apr 2006 → Mar 2012 | diabetes mellitus, glucose intolerance | Tokyo University | Completed | No outcome recorded |
| Phase not applicable6 trials · 1 missed | ||||||
| — | NCT07626840 | Jun 2026 → Jun 2028 expected | acute coronary syndrome | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07524101 | May 2026 → Jan 2031 expected | atherosclerosis, chronic kidney disease, hyperlipidemia | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05705804 | Jun 2023 → May 2027 expected | atherosclerotic cardiovascular disease, hyperlipidemia | Yonsei University | Recruiting | No outcome recorded |
| — | NCT03730038 | Feb 2019 → Feb 2020 | hyperlipidemia | Yonsei University | Completed | No outcome recorded |
| — | NCT02290106 | Mar 2015 → Apr 2018 | NAFLD1, obesity disorder | Massachusetts General Hospital | Completed | Missed primary |
| — | NCT00548145 | Nov 2007 → Oct 2011 | Alzheimer disease, hyperlipidemia | Osaka University | Terminated | No outcome recorded |
| Comparator or background therapy32 trials | ||||||
| Phase 1 | NCT01764178 Comparator | Jan → Mar 2013 | hyperlipidemia, hypertensive disorder | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01406431 Comparator | Aug 2011 | hyperlipidemia, hypertensive disorder | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT00653913 Comparator | Mar → Sep 2004 | — | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT07307989 Comparator | Aug 2025 → Jul 2029 expected | hyperlipidemia, ischemic stroke | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT01890967 Background | Jun 2013 → Apr 2014 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06317051 Comparator | Dec 2024 → Jul 2026 overdue | HIV infectious disease | Kirby Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04643093 Comparator | Aug 2020 → Aug 2021 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02956590 Comparator | May 2018 → Apr 2023 | hyperlipidemia, obesity disorder | Carelon Research | Completed | No outcome recorded |
| Phase 3 | NCT02670434 Comparator | Jan 2016 → Jul 2017 | hyperlipidemia | Kowa Research Institute, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT03618797 Comparator | Nov 2015 → Jan 2018 | hyperlipidemia, combined, 2 | Hanlim Pharm. Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT02107898 Background | Mar 2014 → Jan 2015 | hyperlipidemia | Sanofi | Completed | Met primary |
| Phase 4 | NCT06722521 Comparator | Jul 2025 → Jun 2032 expected | calcinosis | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05537948 Comparator | Oct 2021 → Jan 2024 overdue | hyperlipidemia, liver disorder | National Medical Research Center for Therapy and Preventive Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04061824 Comparator | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02144922 Comparator | May 2014 → Oct 2016 | hypertensive disorder | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01648829 Comparator | Jan 2014 → Dec 2015 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02056847 Comparator | Sep 2013 → May 2017 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT02545231 Comparator | Feb 2013 → Dec 2018 | atherosclerosis | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01660191 Comparator | Dec 2011 → Aug 2013 | hyperlipidemia | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01502904 Comparator | Jul 2010 → May 2015 | myocardial ischemia | Yonsei University | Completed | Met primary |
| Phase 4 | NCT00861861 Comparator | Sep 2008 → Oct 2013 | coronary artery disorder, hyperlipoproteinemia | Kumamoto University | Completed | No outcome recorded |
| Phase 4 | NCT00701285 Comparator | Jul 2008 → May 2013 | congestive heart failure | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT00640276 Comparator | Apr 2008 → Feb 2011 | hyperlipidemia, metabolic syndrome X | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT00549926 Comparator | Oct 2007 → Feb 2010 | coronary artery disorder, hyperlipidemia | Yokohama City University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00242944 Comparator | Nov 2005 → Oct 2007 | coronary artery disorder, hyperlipidemia | Kyoto University | Completed | No outcome recorded |
| — | NCT06001047 Comparator | Nov 2023 → Jul 2026 overdue | benign paroxysmal positional vertigo | Xi'an No.3 Hospital | Recruiting | No outcome recorded |
| — | NCT06096909 Background | Nov 2023 → Nov 2025 overdue | acute coronary syndrome | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT03606824 Comparator | Mar 2019 → Feb 2020 | atherosclerotic cardiovascular disease, hyperlipidemia, hypothyroidism | Shaochun.Li | Unknown | No outcome recorded |
| — | NCT01042730 Comparator | Feb 2010 → Jun 2016 | coronary artery disorder | Juntendo University | Completed | No outcome recorded |
| — | NCT00846118 Comparator | Feb 2009 → Jan 2011 | cardiovascular disorder | Chieko Hamada | Terminated | No outcome recorded |
| — | NCT00711919 Comparator | Jul 2007 → Dec 2009 | carotid artery disorder, hyperlipidemia | Kyoto Prefectural University of Medicine | Unknown | No outcome recorded |
| — | NCT00716846 Comparator | Jun 2006 → Jul 2008 | — | Hamamatsu University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2023-11-21 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Pitavastatin Tablets lupin.com ↗
it has received approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg |
| 2020-12-04 | JW Pharmaceutical | Results [JW중외제약] 이상지질혈증치료제 ‘피타바스타틴’,심뇌혈관질환 예방효과 입증 jw-pharma.co.kr ↗
특히 먼저 출시된 스타틴 제제에 비해 관련 학술근거가 부족했던 피타바스타틴의 효능이 동등함을 확인했다. |
| 2020-03-23 | JW Pharmaceutical | Results [JW중외제약] ‘리바로’, 온라인 국제 학술심포지엄서 연구결과 공개 jw-pharma.co.kr ↗
안정형 관상 동맥 질환이 있는 13,000명 이상의 일본 환자를 대상으로 한 전향적 무작위 시험인 ‘REAL-CAD study’는 피타바스타틴(리바로)의 저용량(1mg) 대비 고용량(4mg)의 이점을 분명히 보여준다 |
| 2017-11-17 | JW Pharmaceutical | Results [JW중외제약] ‘리바로’, 동양인 관상동맥질환 환자에게 효과적 jw-pharma.co.kr ↗
그 결과 ‘리바로 4mg’가 ‘리바로 1mg’ 5.4% 보다 19% 감소시킨 4.3%를 나타냈다. |
| 2017-08-09 | Lupin Limited | Regulatory Lupin receives FDA approval for Nikita™ (Pitavastatin) Tablets lupin.com ↗
Mumbai: Pharma Major Lupin Limited (Lupin) announced that it has received a 505 (b) (2) NDA approval for its NikitaTM (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA). |
| 2016-12-30 | Lupin Limited | Regulatory Lupin Receives Tentative Approval for Generic Livalo® Tablets lupin.com ↗ |
| 2014-12-08 | JW Pharmaceutical | Results [JW중외제약] JW중외제약 고지혈증 치료제 리바로, 대사증후군 개선 효과 최초 입증 jw-pharma.co.kr ↗
총 48주 동안 진행된 임상시험 결과, 리바로를 복용한 환자 중 65%가 콜레스테롤 수치가 낮아지고, 44%의 환자가 대사증후군 환자 분류에서 제외되는 등 비약물군에 비해 월등한 개선 효과가 나타났다. |
| 2013-06-17 | Eli Lilly and Company | Results New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia lilly.com ↗
The results of this pre-specified safety analysis, presented yesterday at the Endocrine Society's 95th Annual Meeting & Expo in San Francisco, CA, showed neutral effects of pitavastatin 4 mg and pravastatin 40 mg on fasting serum glucose (FSG) and HbA1c levels over 12 weeks. |
| 2013-03-07 | Eli Lilly and Company | Results New Superiority Trial Showed LIVALO® (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg lilly.com ↗
Results showed that, after 12 weeks of therapy, pitavastatin had a significantly greater decrease in LDL-C compared with pravastatin (pitavastatin -49.4 mg/dL and pravastatin -33.6 mg/dL, 31% vs 21% reduction in LDL-C, respectively, p < 0.001). |
| 2012-07-22 | Eli Lilly and Company | Results Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO® (pitavastatin) and Protease Inhibitor Combination (darunavir/ritonavir) in Healthy Volunteers lilly.com ↗
The study, presented at the 19th International AIDS Conference in Washington, DC, found that when co-administered, the blood levels for LIVALO and each of the PIs were not significantly affected. |
| 2012-05-31 | Eli Lilly and Company | Results New Data Showed LIVALO® (pitavastatin) Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin lilly.com ↗
LIVALO 4 mg showed superior LDL-C reduction compared with pravastatin 40 mg after 12 weeks of therapy. |
| 2011-07-18 | Eli Lilly and Company | Results New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy lilly.com ↗
The study, presented at the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy, found that when co-administered, the individual drug blood levels for LIVALO or each of the PIs was minimally affected. |
All press releases naming this drug 22 releases
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 108 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pitavastatin | “A total of 293 patients were randomly assigned into four groups receiving 2 mg pitavastatin, 4 mg pitavastatin, 2 mg pitavastatin/10 mg ezetimibe (K-924 LD), and 4 mg...” PMID 36908150 ↗ Mar 2023103“One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “The purpose of this study is to compare the pharmacokinetics and safety of a controlled release (CR) version of pitavastatin (also referred to as NK-104) to immediate release...” NCT02634034 ↗ “The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as "Minshilang" in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd.” NCT06001047 ↗ “A Clinical Trial to Evaluate the Pharmacokinetics of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Under Fed Condition in Healthy Male Volunteers” NCT02250976 ↗ “In this study, the combination therapy strategy will utilize Pitavastatin 1-4 mg plus Ezetimibe 10 mg once daily or Atorvastatin 10-20 mg plus Ezetimibe 10 mg once daily.” NCT07524101 ↗ “Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02107898 ↗ “Pitavastatin is a unique lipophilic statin with moderate efficacy in lowering LDL-C levels by 30% to 50% with a tolerable safety profile.” PMID 36241463 ↗ Oct 2022 “ULREA-PVS-NP is a poly(lactic-co-glycolic acid) (PLGA) nanoparticle formulation containing pitavastatin and administered intravenously.” NCT07774975 ↗ “Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.” NCT06096909 ↗ “Moderate- or high-intensity statin monotherapy, including atorvastatin 10-80 mg/d, rosuvastatin 5-20 mg/d, pitavastatin 1-4 mg/d” NCT07307989 ↗ |
| Known as | Itavastatin calcium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | LIVALO | “To develop combination product of micronized fenofibrate plus pitavastatin, we would like to evaluate the comparative pharmacokinetics and safety of fixed-dose...” NCT02250976 ↗2“Investigational Product Test group: Pitavastatin calcium (LIVALO) 4mg tab Control group: Pitavastatin calcium (LIVALO) 2mg tab” NCT02056847 ↗ |
| Known as | Livalo Tab 1 mg | “Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be...” NCT00301392 ↗ |
| Known as | Livaro | “* Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg” NCT02250976 ↗ |
| Known as | Minshilang | “The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as "Minshilang" in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd.” NCT06001047 ↗ |
| Known as | Nikita | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | NK-104 | “The purpose of this study is to compare the pharmacokinetics and safety of a controlled release (CR) version of pitavastatin (also referred to as NK-104) to immediate release...” NCT02634034 ↗3“Pitavastatin (NK-104)” NCT01422382 ↗ “Pitavastatin (NK-104)” NCT01057433 ↗ “Pitavastatin (NK-104)” NCT01422369 ↗ |
| Known as | NSC-760423 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | pitavastatin Ca | “To develop combination product of micronized fenofibrate plus pitavastatin, we would like to evaluate the comparative pharmacokinetics and safety of fixed-dose...” NCT02250976 ↗1“Livaro tab. 2mg (pitavastatin Ca 2mg) by Joong Wae Pharm.” NCT01767610 ↗ |
| Known as | Pitavastatin calcium | “Nondiabetic, obese, HTG males (n = 12) received pitavastatin calcium (4 mg/day) for 180 days in a single-phase, unblinded study.” PMID 38160756 ↗ Dec 20231“Investigational Product Test group: Pitavastatin calcium (LIVALO) 4mg tab Control group: Pitavastatin calcium (LIVALO) 2mg tab” NCT02056847 ↗ |
| Known as | Pitavastatin calcium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | Pitavastatin Calcium Tablets | “The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as "Minshilang" in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd.” NCT06001047 ↗ |
| Known as | Pitavastatin component of k-924 pivastatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | PITAVASTATIN MAGNESIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | PITAVASTATIN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | Pitavastatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | Pitavastatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Known as | Zypitamag | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201753 ↗ |
| Action | Inhibit | “Pitavastatin is a novel, potent, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.” PMID 21874537 ↗ Aug 20111“HMG-CoA reductase inhibitor” CHEMBL1201753 ↗ |
| Modality | Small molecule | “Pitavastatin is a chemically synthesized statin in Japan” NCT00242944 ↗ |
| Route | Oral | “2 mg by orally/day” NCT00548145 ↗ |
| Target | HMGCR | “HMG-CoA reductase inhibitor” CHEMBL1201753 ↗ |